Ojai Retinal Technology, LLC – Trademark Portfolio
Entity Type: 16
Ojai Retinal Technology, LLC holds 45 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 45 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 16 trademarks are registered and 7 are pending. Notable registered marks include SDM, SAPRA, SAFE-PULSE, CHOOSE PREVENTION, and DYNAMIC DOSIMETRY. The owner is based in Los Angeles, CA.
#88
10580 Wilshire Blvd
Los Angeles, CA 90024
Showing of trademarks Trademarks
Trademark Classifications
Ojai Retinal Technology, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Ojai Retinal Technology, LLC have?
Ojai Retinal Technology, LLC has 45 U.S. trademarks filed with the USPTO. Of these, 16 registered, 7 pending, 20 abandoned, 2 cancelled.
What trademark classes does Ojai Retinal Technology, LLC file in?
Ojai Retinal Technology, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 10 (Medical Apparatus). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.
What are Ojai Retinal Technology, LLC's most well-known trademarks?
Ojai Retinal Technology, LLC's registered trademark portfolio includes well-known marks such as SDM, SAPRA, SAFE-PULSE, CHOOSE PREVENTION, and DYNAMIC DOSIMETRY. These are among 16 currently registered trademarks in the portfolio.
What is Ojai Retinal Technology, LLC's trademark registration success rate?
Ojai Retinal Technology, LLC has a 42% trademark registration rate, with 16 out of 38 resolved applications resulting in successful registration. Currently, 7 applications are pending review.